Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBN6IE)

Drug Name

ADS-103274 Drug Info

Synonyms

ADS-103274; CHEMBL276393; BDBM50241099

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanin-concentrating hormone receptor 1 (MCHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-830216	DMCW71N	Obesity	5B81	Phase 1	[2]
AZD1979	DMQ1OX4	Obesity	5B81	Phase 1	[3]
PMID25522065-Compound-27	DMXN4KB	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-29	DMBNAK9	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-34	DMZDIRQ	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-39	DM5YMQH	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-40	DMCIQ01	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-11	DM410Z6	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-50	DMBWA0V	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-12	DMVKO9C	N. A.	N. A.	Patented	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[5]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[6]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[7]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[8]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[9]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[10]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[11]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[11]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[11]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Inhibitor	[1]
Melanin-concentrating hormone receptor 1 (MCHR1)	TTX4RTB	MCHR1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
2	2011 Pipeline of Bristol-Myers Squibb.
3	Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
4	Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
5	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
6	Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
7	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
8	New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
9	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
10	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
11	Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.